BioSpace News Archive

An Arthritis Research Canada study has revealed substantial survival benefit associated with the current use of hydroxychloroquine (HCQ), and increased mortality with recent discontinuation among individuals with systemic lupus erythematosus (SLE) in the general population.

Masimo Corporation (Nasdaq: MASI) today announced a change to its 2020 Annual Meeting of Stockholders

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting.

Submission for the treatment of anemia in adult patients with chronic kidney disease [20-May-2020] TOKYO and SAN FRANCISCO , May 20, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno , “FibroGen”) today announced the marketing authorization applicatio

Avantor, Inc. announced the pricing of the previously announced underwritten secondary offering of 45,000,000 shares of the Company’s common stock held by certain of its stockholders pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission, at the public offering price of $16.25 per share.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the U.S. Food and Drug Administration approved the BRACAnalysis CDx® test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza®.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced the closing of a $20 million Series A financing of Zentera Therapeutics, a biopharmaceutical company with headquarters in Shanghai, China.

TearClear Corp., an emerging Ophthalmic Pharmaceutical Company, has announced the appointment of Amir Shojaei, Pharm.D., Ph.D., as Chief Development Officer, a major step towards planning and executing multiple clinical development and registration programs.

Morgan Stanley executive brings extensive life sciences sector strategic and financial expertise to pioneering proteomics company

On track to report progression free survival and overall survival data from triple combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020